LakeShore Biopharma
LSB was delisted on the 19th of September, 2025.
7 hedge funds and large institutions have $2.23M invested in LakeShore Biopharma in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 5 closing their positions.
0.1% less ownership
Funds ownership: 0.27% → 0.17% (-0.1%)
33% less capital invested
Capital invested by funds: $3.34M → $2.23M (-$1.11M)
36% less funds holding
Funds holding: 11 → 7 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$25.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$910K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$103K |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$61.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$26.4K |
| 5 |
OCM
Ovata Capital Management
Hong Kong
|
-$10.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Fidelity Investments
Boston,
Massachusetts
| $803K | – | – | – |
|
|
HA
2
HHLR Advisors
Grand Cayman,
Cayman Islands
| $513K | – | – | – |
|
|
3
Fidelity International
Hamilton,
Bermuda
| $424K | -$61.1K | -11,794 | -16% |
|
|
SCM
4
Superstring Capital Management
New York
| $212K | – | – | – |
|
5
Barclays
London,
United Kingdom
| $169K | – | – | – |
|
|
6
Bank of Montreal
Toronto,
Ontario, Canada
| $75.5K | -$103K | -19,889 | -68% |
|
|
7
UBS Group
Zurich,
Switzerland
| $33.7K | +$25.6K | +4,942 | New |
|
|
O
8
OrbiMed
New York
| – | -$910K | -140,428 | Closed |
|
|
OCM
9
Ovata Capital Management
Hong Kong
| – | -$10.2K | -15,000 | Closed |
|
|
10
Citadel Advisors
Miami,
Florida
| – | -$26.4K | -4,068 | Closed |
|
11
Geode Capital Management
Boston,
Massachusetts
| – | -$8.82K | -1,361 | Closed |
|
12
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$7.56K | -1,167 | Closed |
|
LSB Hedge Fund Activity: Q3 2024 in Review
7 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q3 2024, worth a combined $2.23M — down 33% from $3.34M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of LSB and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was UBS Group, opening a new position worth an estimated $25.6K. The largest seller was OrbiMed, exiting entirely with an estimated $910K sold.
- 7 institutional investors held LakeShore Biopharma (LSB) as of Q3 2024, down from 11 in Q2 2024.
- Funds reported $2.23M of LakeShore Biopharma stock for Q3 2024, down 33% quarter-over-quarter.
- 1 fund opened new LakeShore Biopharma positions in Q3 2024 and 5 closed out, a net change of -4 holders.
- The largest LakeShore Biopharma buyer in Q3 2024 was UBS Group, an estimated $25.6K added.
- The largest LakeShore Biopharma seller in Q3 2024 was OrbiMed, an estimated $910K sold.
Based on aggregated 13F filings for Q3 2024.